| 產品名稱 |
Equid herpesvirus 4 |
| 商品貨號 |
B241895 |
| Classification |
Herpesviridae, Varicellovirus |
| Deposited As |
Equine herpesvirus type 4 |
| Agent |
Equid herpesvirus 4 |
| Strain |
405/76 |
| Common Name |
Equine herpesvirus 4 |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen 1 mL per vial |
| Storage Conditions |
?-70°C or colder |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Comments |
Endemic to horses in the United States. |
| Effect on Host |
?CPE CPE |
| Recommended Host |
Production Host: ?BS-C-1 (ATCC? CCL-26™) BS-C-1 (ATCC CCL-26) |
| Growth Conditions |
Temperature: 37°C Incubation: 1-2 days |
| Name of Depositor |
MJ Studdert, The University of Melbourne |
| U.S. Patent |
|
| U.S. Patent Number |
|
| Special Collection |
ATCC |
| Source |
Aborted equine fetus, Australia |
| References |
Studdert MJ. Vaccine for equine herpesvirus. U.S. Patent 5,084,271 dated January 28 1992.
Fitzpatrick DR, Studdert MJ. Immunologic relationships between equine herpesvirus type 1 (equine abortion virus) and type 4 (equine rhinopneumonitis virus). Am. J. Vet. Res. 45: 1947-1952, 1984. PubMed: 6208822
|
